AGEN7:30 AMAgenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Canceragenusbio.com
AGEN4:30 PMAgenus to Provide Second Quarter 2026 Financial Report and Development Updateagenusbio.com
AGEN10:28 AMAgenus Announces Three BOT+BAL Presentations Spanning Neoadjuvant and Late-Line Colorectal Cancer and Advanced Sarcomas at ESMO 2026agenusbio.com